Diagonal Therapeutics: Funding, Investors & Team (Sep 2026)
Diagonal Therapeutics is a biotechnology company that develops targeted therapies for cancer by integrating molecular biology, genomic data, and translational research to identify and advance precision oncology drug candidates. Its platform focuses on genetically defined cancer dependencies and novel mechanisms of action to create small molecule and biologic therapies that aim to disrupt key pathways driving tumor growth and survival. The company’s research approach combines target discovery, medicinal chemistry, and preclinical validation to progress programs toward clinical evaluation with the goal of addressing unmet needs in oncology. Diagonal Therapeutics also collaborates with academic partners and leverages external datasets to inform its therapeutic strategies and enhance predictive models for treatment response. Its pipeline includes programs across multiple cancer types that are designed to exploit specific genetic or phenotypic vulnerabilities in tumor cells.
Diagonal Therapeutics has raised $125M across 1 funding round on record, the most recent a Series B of $125M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Diagonal Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Diagonal Therapeutics Funding Rounds
Diagonal Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Diagonal Therapeutics Funding Compared to Other Biotechnology Startups
Diagonal Therapeutics' latest round of $125M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Diagonal Therapeutics in Biotechnology and Watertown
Companies Similar to Diagonal Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Diagonal Therapeutics Funding FAQs
What does Diagonal Therapeutics do?
Diagonal Therapeutics is a biotechnology company that develops targeted therapies for cancer by integrating molecular biology, genomic data, and translational research to identify and advance precision oncology drug candidates. Its platform focuses on genetically defined cancer dependencies and novel mechanisms of action to create small molecule and biologic therapies that aim to disrupt key pathways driving tumor growth and survival. The company’s research approach combines target discovery, medicinal chemistry, and preclinical validation to progress programs toward clinical evaluation with the goal of addressing unmet needs in oncology. Diagonal Therapeutics also collaborates with academic partners and leverages external datasets to inform its therapeutic strategies and enhance predictive models for treatment response. Its pipeline includes programs across multiple cancer types that are designed to exploit specific genetic or phenotypic vulnerabilities in tumor cells.
How much funding has Diagonal Therapeutics raised?
Diagonal Therapeutics has raised $125M across 1 round on record. The most recent is a Series B of $125M announced in Jan 2026.
When did Diagonal Therapeutics last raise funding?
Diagonal Therapeutics' most recent funding round on record is a Series B of $125M, announced in Jan 2026.
Who founded Diagonal Therapeutics?
FundedIQ lists Alexey Lugovskoy (Founder) at Diagonal Therapeutics.
Where is Diagonal Therapeutics headquartered?
Diagonal Therapeutics is based in Watertown, Massachusetts, United States.
How many employees does Diagonal Therapeutics have?
Diagonal Therapeutics is in the 11-50 employee band.
How does Diagonal Therapeutics' funding compare to other Biotechnology startups?
Diagonal Therapeutics' latest round of $125M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Diagonal Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Diagonal Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.